Anti–PD-1 therapy should be permanently discontinued for severe (grade 3) or life-threatening (grade 4) pneumonitis and withheld until resolution for moderate (grade 2) pneumonitis (Bristol-Myers Squibb, 2016; Merck, 2015a). The gene discussed is PDCD1; the disease is pneumonitis.